Skip to Main Content

And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is modest and also abbreviated, since we will eventually make our way to a celebrated, if overcrowded, event starting early next week where biopharma and finance folks huddle and hondel. But what about you? If you are heading to the same destination, well, we hope you have an easy trip. As for the rest of you, this may be a good time to catch up on sundry errands, that growing reading list, or reaching out to someone special. Or maybe a few long naps are in order. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you soon.

Combining multiple antibiotics may make bacteria more likely to develop resistance, Scientific American writes. A new study suggests that drug combinations can actually speed the development of resistance, and although small, the study reveals a major threat to the way doctors currently think about combination antibiotics. “Our entire approach to antibiotics is going to have to be rethought,” said Ramanan Laxminarayan, director of the Center for Disease Dynamics, Economics and Policy in Washington, D.C., who was not involved in the work.


A requirement that drug makers disclose list prices in television ads heads to a federal appeals court on Jan. 13 in a case that will test government authority to regulate commercial speech, Bloomberg Law notes. Merck (MRK), Eli Lilly (LLY), and Amgen (AMGN), along with the Association of National Advertisers, argue the Department of Health and Human Services cannot compel speech by requiring them to include the list price — particularly because that number can be misleading.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!